Weekly Top News – Psoriasis – May 27, 2019

May 27, 2019

Cosentyx (secukinumab) / Novartis
Cosentyx: Regulatory approval in China for psoriasis at the end of 2019 (Novartis) – May 25, 2019 – Investor Event: Regulatory approval in China for ankylosing spondylitis at the end of 2020
[Screenshot]

 

Cosentyx (secukinumab) / Novartis
Cosentyx: Data from P3 EXCEED trial (NCT02745080) for psoriatic arthritis in 2019/2020 (Novartis) – May 25, 2019 – Investor Event: Data from P3 SURPASS trial (NCT03259074) for ankylosing spondylitis in 2022
[Screenshot]

 

benvitimod (GSK2894512) / Roivant
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) (clinicaltrials.gov) – May 20, 2019 – P3; N=500; Not yet recruiting; Sponsor: Dermavant Sciences GmbH

 

Cosentyx (secukinumab) / Novartis
Cosentyx: Data from P2 ARROW trial (NCT03553823) for plaque psoriasis at the end of 2019 (Novartis) – May 25, 2019 – Investor Event
[Screenshot]

 

ANB019 / AnaptysBio
ANB019: Top-line data from P2 POPLAR trial (NCT03633396) for palmoplantar pustulosis in H1 2020 (Bank of America Merrill Lynch Health Care Conference 2019, AnaptysBio) – May 23, 2019
[Screenshot]

 

ABBV-157 / AbbVie, Inventiva
ABBV-157: Initiation of P1 trial (NCT03922607) for chronic plaque psoriasis in May 2019 (Inventiva) – May 21, 2019 – Company presentation: Completion of P1 trial for chronic plaque psoriasis in September 2020
[Screenshot]

 

PF-06700841 / Pfizer
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis (clinicaltrials.gov) – May 24, 2019 – P2b; N=196; Not yet recruiting; Sponsor: Pfizer

 

Stelara (ustekinumab) / J&J
A Case of Eosinophilic Pneumonia Secondary to Ustekinumab in the Treatment of Crohn’s Disease (ATS 2019) – May 24, 2019 – Abstract #A1476/P475; Pres time: May 19, 2019; 11:15 AM – 01:00 PM; Location: Area D (Hall F, Level 2), KBHCCD; “…His treatment regimen included methotrexate for over one year and he had received his first dose of ustekinumab 6 weeks prior to presentation…Cefepime, metronidazole, azithromycin and vancomycin were initiated…The patient was treated with Methylprednisolone 500 mg IV for 3 days, tapered to 125 mg IV for 3 days, followed by a six week prednisone taper…Ustekinumab has also been associated with hypersensitivity pneumonitis and interstitial lung disease with a granulomatous component. In patients taking ustekinumab with respiratory failure and parenchymal opacities on chest radiograph, eosinophilic pneumonia should be considered.”

No Comments

Post a Comment

Comment
Name
Email
Website